Summary:
A 52-Week study comparing the efficacy and safety of once weekly IcoSema and once weekly semaglutide, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with a GLP-1 recepter agonist.
Qualified Participants Must:
• At least 18 years old
•
Have Type 2 Diabetes
•
HbA1c of 7.0 to 10.0%
•
Never been on Insulin
•
Treated with a stable dose of daily or weekly GLP-1 receptor agonist
Qualified Participants May Receive:
Compensation for time and travel.